Evolus, Inc. Common Stock (EOLS) is a publicly traded Healthcare sector company. As of July 10, 2026, EOLS trades at $6.80 with a market cap of $447.15M and a P/E ratio of -10.22. EOLS moved +0.74% today. Year to date, EOLS is +3.01%; over the trailing twelve months it is -29.09%. Its 52-week range spans $3.86 to $17.12. Analyst consensus is strong buy with an average price target of $14.50. Rallies surfaces EOLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Conexeu Completes P.R.O.O.F Study, Targets Q1 2027 510(k) Push: Conexeu Sciences completed the 12-month P.R.O.O.F preclinical study for its CXU collagen platform, meeting objectives across facial, body and mechanical performance pillars. The company plans a predicate-based 510(k) submission for its lead injectable device in Q1 2027, intensifying competition in medical aesthetics for Evolus.
| Metric | Value |
|---|---|
| Price | $6.80 |
| Market Cap | $447.15M |
| P/E Ratio | -10.22 |
| EPS | $-0.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.12 |
| 52-Week Low | $3.86 |
| Volume | 721.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $301.79M |
| Net Income | $-43.42M |
| Gross Margin | 66.06% |
5 analysts cover EOLS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.50.